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Although inhibition of natural killer (NK) cell-mediated lysis by the class I HLA molecules 
of target cells is an established phenomenon, knowledge of the features of class I molecules which 
induce this effect remains rudimentary. Using class I alleles HLA-B*1502 and B'1513 which 
differ only at residues 77-83 which define the Bw4 and Bw6 serological epitopes, we tested 
the hypothesis that the presence of the Bw4 epitope on class I molecules determines recognition 
by NKB1 + NK cells. HLA-B*1513 possesses the Bw4 epitope, whereas B'1502 has the Bw6 
epitope. Lysis by NKB1 + NK cell clones of transfected target cells expressing B'1513 as the 
only HLA-A, -B, or -C molecule was inhibited, whereas killing of transfectants expressing B'1502 
was not. Addition of an an anti-NKB1 monoclonal antibody reconstituted lysis of the targets 
expressing B'1513, but did not affect killing of targets bearing B'1502. The inhibitory effect 
of B'1513 could be similarly prevented by the addition of an anti-class I monoclonal antibody. 
These results how that the presence of the Bw4 epitope influences recognition of HLA-B molecules 
by NK cells that express NKB1, and suggest hat the NKB1 molecule may act as a receptor 
for Bw4 + HLA-B alleles. Sequences outside of the Bw4 region must also affect recognition by 
NKB1 § NK cells, because lysis of transfectants expressing HLA-A*2403 or A'2501, which 
possess the Bw4 epitope but are in other ways substantially different from HLA-B molecules, 
was not increased by addition of the anti-NKB1 antibody. Asparagine 86, the single site of N-linked 
glycosylation on dass I molecules, is in dose proximity to the Bw4/Bw6 region. The glycosylation 
site of the Bw4-positive molecule B'5801 was mutated, and the mutant molecules tested for 
inhibition of NKB1 § NK cells. Inhibition that could be reversed by addition of the anti-NKB1 
monoclonal antibody was observed, showing the presence of the carbohydrate moiety is not 
essential for class I recognition by NKB1 § NK cell clones. 
N 'K cells are a subset of lymphocytes which display spon- taneous cytotoxicity for a variety of target cells (1). Al- 
though cytolysis by NK cells is MHC unrestricted, recent 
evidence indicates that interactions with class I HLA antigens 
can regulate NK cell function. In contrast to MHC-restricted 
T cells, which require HLA antigens for target cell lysis, class 
I expression appears to inhibit lysis by NK cells. Initial ob- 
servations correlated low class I MHC expression with the 
sensitivity of tumor cell lines to natural killing (2). Transfec- 
tion of class I genes into susceptible target cells provided pro- 
tection from lysis by NK cells, demonstrating that inhibi- 
tion was caused by class I (3, 4). Inhibition is dependent upon 
the class I allele, since in one study several transfected HLA-A 
and -B alleles provided protection, but HLA-A*0201 did not 
(5). Characterization f the patterns of lysis of a panel of class 
I transfected target cells by NK cell clones, demonstrated that 
killing is usually inhibited by multiple class I alleles, and in- 
dicated the existence of considerable heterogeneity in the HLA 
specificity of NK cell clones (6). From these observations it 
appears NK cells recognize polymorphic HLA antigens, and 
this interaction inhibits target cell lysis. 
Attention has been focused on the role of HLA-C antigens 
in governing NK cell lysis, by observations that expression 
of self or related HLA-C molecules exerts a dominant in- 
hibitory effect on target cell lysis by NK cells (7). NK cells 
appear to distinguish two groups of HLA-C alleles based on 
a diaUelism at residues 77 and 80 of the heavy chain sequence. 
Two potential receptors of 58 kD molecular mass, which may 
be involved in recognition of the HLA-C groups, have been 
identified by Moretta nd colleagues (8). NK cell clones which 
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express these p58 molecules fail to lyse targets bearing cer- 
tain HLA-C alleles, and killing is restored in the presence 
of anti-p58 monoclonal antibodies (8). 
Recently, another putative NK cell receptor for HLA has 
been identified (9). This molecule, called NKB1, is distinct 
from the p58 molecules, in that it has a molecular mass of 
70 kD and appears to confer eactivity with certain HLA-B 
alleles. NK cell clones bearing NKB1 were always inhibited 
by target cell expression of HLA-B* 5801, B* 5101, and B'2705, 
but not by other HLA-B alleles, or by HLA-A and -C alleles 
(9). Sequence analysis of the inhibitory alleles suggests that 
reactivity might correlate with the Bw4 public epitope. 
Every HLA-B allele possesses one of two mutually exclu- 
sive serological epitopes known as Bw4 and Bw6 (10). Bw6 
is present on approximately 2/3 of HLA-B alleles, while Bw4 
is on the remaining 1/3. These epitopes appear to be evolu- 
tionarily ancient features of class I molecules, since related 
determinants are found on class I molecules from non-human 
primate species (11). Bw4 and Bw6 were originally thought 
to define two HLA-B antigens, but were later recognized 
to represent shared eterminants of a much larger family of 
polymorphic alleles (12). Such shared eterminants are known 
as public epitopes (13). Bw6 is only found on HLA-B alleles; 
Bw4 is found on HLA-B and some HLA-A alleles. 
Sequence comparisons ofalleles possessing the Bw4 or Bw6 
epitope indicated that the residues involved in forming these 
determinants map to positions 77-83 of the class I molecule 
(14, 15). Analysis of HLA-A and B molecules which react 
with Bw4 alloantisera, reveals ome heterogeneity n the amino 
acids comprising this determinant, while alleles that possess 
the Bw6 epitope are invariant in this region, with the excep- 
tion of one allele, 8"7301 (16, 17). Serology has identified 
many pairs of HLA-B alleles which appear to differ only at 
the Bw4/Bw6 region, and determination fthe primary struc- 
tures of these antigens has proved this prediction correct. Thus 
this region has apparently been the subject of frequent gene 
conversion events. 
These observations have led to much speculation as to the 
possible function of the Bw4 and Bw6 epitopes (10). Some 
of the polymorphic residues that define these epitopes are 
thought o interact with bound peptides, so they may influence 
peptide specificity (18). Differences in this region can also 
affect T cell recognition (19). However, to date no clear func- 
tion has been assigned to the Bw4 and Bw6 epitopes. The 
potential association of Bw4 with NK cell reactivity may 
therefore help to clarify the function of these determinants. 
Residues 77-83 which determine the Bw4/Bw6 epitopes 
are in close proximity to asparagine 86, the highly conserved 
site of N-linked glycosylation on class I molecules (20). In- 
deed, for human class I molecules, this is the only known 
site of glycosylation. The carbohydrate moiety is not required 
for cell surface expression of class I molecules (21, 22) and 
its function remains unclear. The finding that Ly-49, a mu- 
fine NK cell receptor which binds H-2D d (23, 24), contains 
an extracellular domain with homology to mammalian C-type 
lectins, raises the possibility that carbohydrate binding may 
be involved in NK cell interactions with class I molecules. 
The experiments described here were designed to inves- 
tigate class I recognition by NK cells bearing the NKB1 sur- 
face antigen. To test the hypothesis that the putative NK cell 
receptor NKB1 is influenced by the Bw4/Bw6 diallelism, 
we examined the inhibitory effect of two HLA-B molecules 
which differ only at these epitopes. The importance of the 
carbohydrate moiety in class I recognition by NKB1 + NK 
cells was also investigated using class I molecules mutated 
at the site of glycosylation. 
Materials and Methods 
Preparation of NK Cell Clones. Mononuclear cells from the pe- 
ripheral blood of two healthy adults were isolated by density cen- 
trifugation with Ficoll-Hypaque (Pharmacia LKB Biotechnology 
Inc., Piscataway, NJ). PBMC were stained with FITC-conjugated 
anti-CD56 mAb (Leu 19), and PE-conjugated anti-NKB1 (DXg), 
and Cychrome-conjugated anti-CD3 (Leu 4). NK cells (CD56 +- 
CD3-) which expressed NKB1, were cloned at one cell per well 
using a single cell deposition system of the FACStar Prus flow 
cytometer (Becton Dickinson Immunocytometry Systems, Moun- 
tain View, CA). Clones were established using culture conditions 
described previously (25). All clones generated by this procedure 
had the cell surface phenotype CD3-, CD56 ~, NKB1 § and 
mediated NK cytolytic function. 
Target CelIPanel. Class I HLA cDNA was prepared from EBV- 
transformed cell lines, subcloned into the phage M13 vector and 
sequenced as described (26). cDNAs encoding HLA-A*0201, 
A*0211, A'2403, A'2501, A'3601, B*0702, B'1501, B'1502, 
B'1508, B'1513, B'3505, B'4801, B'5501, B'5801, Cw*0102, 
Cw*0304, Cw*0401, Cw*0801, and Cw* 1503 were subcloned into 
the expression vector pBJl-neo (27, kindly provided by Dr. Mark 
Davis, Stanford University, Palo Alto, CA). The class I HLA-A, 
B, and C negative B lymphoblastoid cell line, 721.221 (28), was 
transfected by electroporation at250V and 960/~F in a 0.4-cm 
gapped cuvette with pBJl-neo containing the class I HLA cDNAs, 
and grown under G418 drug selection (1mg/ml). Cells were stained 
with the monomorphic anti-HLA-A, B, and C mAb W6/32 con- 
jugated to fluorescein (W6/32-F1), and those cells expressing high 
surface levels of class I antigen were sorted using a FACStar PtUs 
flow cytometer (Becton Dickinson). A construct containing the 
HLA-B*2705 gene subcloned into the pHEBo expression vector 
(29) was transfected into the 721.221 cell line by electroporation 
and cells were grown under 300/~g/ml hygromycin drug selec- 
tion. The B'5101/721.221 transfectant was generously provided 
by Dr. Robert DeMars (University of Wisconsin, Madison, WI). 
Flow Cytometry. Methods of immunofluorescent staining and 
flow cytometric analysis were as described (30). Analysis was per- 
formed on a FACScan flow cytometer (Becton Dickinson). For flow 
cytometric analysis the W6/32 mAb was conjugated to fluores- 
cein (W6/32-F1) by reaction with fluorescein-X-NHS (Molecular 
Probes, Inc., Eugene, OR). 721.221 cells transfected with the class 
I HLA alleles listed above were stained with W6/32-F1 and moni- 
tored by flow cytometry on a regular basis to assess the level and 
uniformity of class I HLA antigen surface xpression. 
Preparation ofmAb and F(al/)2. The DX9 mAb precipitates a 
single 70-kD band from NK cells (9). The DX15 mAb precipitates 
a non-disulfide-linked dimer consisting of polypeptides identical 
in mobility to the class I HLA heavy chain and fl2-microglobulin, 
and specifically stains 721.221 HLA transfectants but not the un- 
transfected 721.221 cell line. The DX9 and DX15 IgG~ hybrid- 
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omas were generated byimmunization ofBALB/c mice with with 
the human NK clone VL186-1 (CD3-, CD16 +, CD56 +) and fu- 
sion of their splenocytes with the Sp2/0 myeloma cell line (9). As- 
cites was obtained, and IgG was purified by caprylic acid precipita- 
tion, followed by saturated ammonium sulfate precipitation. 
F(ab')2 fragments were prepared by digesting DX15 IgG with im- 
mobilized pepsin (10 mg/ml in 10 ml of 0.2M sodium citrate, 0.15 
M NaCI buffer, pH 3.5, with 2.5 ml immobilized pepsin for 2 
h at 37~ (Pierce Chemical Co., Rockford, IL). Fc-containing 
species were then removed by protein A affinity chromatography. 
The F(ab')2 fragment preparation was determined tobe pure by 
SDS-PAGE analysis. 
Cell-mediated Cytotoxicity. Cell killing was measured using a 
standard 4-h 51Cr-radioisotope release assay (31). Percent lysis was 
calculated by the formula: 
(Experimental cpm - spontaneous cpm)/(Total cpm - 
spontaneous cpm) x 100 = % lysis 
All assays were carried out using an effector to target ratio of 6:1. 
Antibodies, DX9 mAb or DX15 F(ab')2, were added where 
specified to a final concentration f 6.7 #g/ml. Assays were per- 
formed in duplicate or triplicate, and were repeated from two to 
five times for each clone. Only assays in which the specific lysis 
of the untransfected 721.221 cell line was >130% were included in 
the analysis. 
Site-directed Mutagenesis of HLA-B5801. Two mutants were 
made: in one Asn 86 was replaced by Gln, and in the other Set 
88 was replaced by Ala. Purified B'5801 cDNA was subcloned into 
the phage M13 vector and used as a template for site-directed muta- 
genesis. Two first step PCR reactions were performed with primers 
encoding the desired mutation and primers that bind either to the 
3' end or the 5' end of the B'5801 cDNA, outside of the coding 
region. The PCR products from this reaction were then combined, 
and a second PCR reaction was performed, using only the outside 
primers. The complementary primer pairs used were as follows: 
for the B58.Q86 mutant, 5'-CTCCGCTACTACCAACAGAGC- 
GAGGCCGGG-3' and 5'-CCCGGCCTCGCTCTGTTGGTAGTA- 
GCGGAG-Y. For the B58.A88 mutant, 5'-CTCCGCTACTAC- 
AACCAGGCCGAGGCCGGG-Y and 5'-CCCGGCCTCGGC- 
CTGGTTGTAGTAGCGGAG-3'. For binding to the 5' end of the 
B'5801 cDNA the following primer encoding a SalI restriction 
site was used: 5'-GGGCGTCGACGGACTCAGAATCTCCCC- 
AGACGCGAG-Y. For binding to the 3' end of the B'5801 cDNA 
the following primer encoding a HindlII restriction site was used: 
5'-CCGCAAGCTTCTGGGGAGGAAACACAGGTCAGCATG- 
GGAAC-3'. The final PCR products were digested with tall and 
HindlII restriction endonucleases and subcloned into the pBJl-neo 
expression vector. DH5ot Escherichia coli bacteria were then trans- 
formed with the vector containing the insert cDNA. Vector DNA 
was prepared from individual bacterial colonies, and the class I cDNA 
insert was sequenced completely to ascertain the presence of the 
desired mutations and the absence ofnucleotide misincorporations 
introduced during the PCR reactions. 721.221 cells were then elec- 
troporated with the vector containing the mutated class I insert, 
as described above. 
Immunoprecipitation, SDS-PAGE, and lEF Analysis. 721.221 class 
I FILA transfectants were biosynthetically labeled with 3sS-Cys and 
3sS-Met (Amersham Corp., Arlington Heights, IL), the cells were 
then lysed and class I HLA molecules immunoprecipitated with 
the anti-class I monoclonal ntibody W6/32 as described (32). lm- 
munoprecipitates were divided into four aliquots, and subjected 
to digestion with neuraminidase type VI (Sigma Chemical Co., 
St. Louis, MO) for 3 h, or N-glycanase (Genzyme Corp., Cam- 
bridge, MA) for 16 h, or mock treated with 0.05 M EDTA or PBS, 
respectively. Samples treated with and without neuraminadase were 
subjected toone-dimensional isoelectric focusing el electropho- 
resis, and autoradiography. Samples treated with and without 
N-glycanase were subjected to10 and 12% Tris-glycine polyacryl- 
amide gel electrophoresis, and autoradiography. 
Results 
The molecules chosen for study were 8"1502 and B*1513, 
which encode the serological specificities HLA-B75 and HLA- 
B77, respectively. These antigens are characteristically found 
in southeast Asian populations (33). The B* 1502 and B* 1513 
heavy chain sequences differ only within residues 77-83 of 
the c~1 helix, the region which determines the Bw4 and 
Bw6 epitopes (33). Cells of the mutant cell line 721.221, which 
does not express HLA-A, -B, or -C, were transfected with 
class I HLA cDNA, resulting in cell cultures expressing just 
one HLA-A, -B, or -C antigen. These cells were used as targets 
for a panel of NK cell clones that express the NKB1 mole- 
cule. A reduction of lysis of the transfectant compared to the 
untransfected 721.221 cell line indicated an inhibitory effect 
of the class I allele. To assess the involvement of the NKB1 
molecule, assays were performed in the presence and absence 
of the anti-NKB1 monoclonal antibody, Dxg. 
NKB1 + NK Cells Are Inhibited by B'1513 But Not by 
B'1502. NK cell clones bearing the NKB1 surface antigen 
were generated from two peripheral blood donors, and the 
HLA specifidty of ten clones from each donor examined. Un- 
transfected 721.221 cells were killed effectively by all of the 
NK cell clones, and this killing was unaffected by the pres- 
ence of the anti-NKB1 antibody (Fig. 1 a). By comparison, 
all of the clones howed reduced lysis of transfectants expressing 
B'5801, a known inhibitory allele (9). In the presence of the 
anti-NKB1 antibody, however, lysis of the B'5801 transfec- 
tants was increased to a level comparable to that of the un- 
transfected 721.221 cell line (Fig. 1 b). The pattern of lysis 
seen for 721.221 cells expressing the B'1502 molecule was 
the same as that seen for untransfected cells: each clone effec- 
tively lysed the B'1502 transfectant and no change was seen 
on inclusion of the antibody (Fig. 1 c). In contrast, the pat- 
tern of lysis obtained with the B" 1513 transfectant was similar 
to that of the B'5801 transfectant: lysis was reduced com- 
pared to the untransfected cells, but was elevated to equiva- 
lent levels in the presence of the anti-NKB1 monoclonal n- 
tibody (Fig. 1 at). These different patterns of lysis were not 
due to differences in the class I expression levels of the B* 1502 
and B'1513 transfectants, since the two have comparable ex- 
pression as monitored by flow cytometry (data not shown). 
This experiment shows that B'1513 is able to inhibit lysis 
by NK_B1 + NK cell clones, and that this inhibition can be 
prevented by addition of the anti-NKB1 monoclonal anti- 
body. In contrast, killing is unaffected by the closely related 
B'1502 molecule. Since these alleles differ only at the 
Bw4/Bw6 epitope, this result indicates that the presence of 
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Figure 1. Recognition of HLA- 
B'1513 but not B'1502 class I al- 
leles by NKB1 + NK cell clones. 
Percent lysis of class I HLA trans- 
fected 721.221 target cells by 
NKBI* NK cell clones: (a) Un- 
transfected; (b) B'5801 tranfectant; 
(c) B'1513 transfectant; (d) B'1502 
tranfectant. Dark bars show killing 
in the absence of the anti-NKB1 
mAb, Dxg. Light bars show killing 
in the presence of Dxg. All of the 
NK cell clones were established 
from a single blood donor. 
the Bw4 epitope on HLA-B molecules confers reactivity with 
NKB1 + NK cells. 
This thesis is supported by examination of NKB1 + NK 
cell reactivity with a panel of transfected 721.221 target cells 
each expressing a different HLA-A, -B, or -C molecule (Table 
1). All of the NKB1 + NK clones showed diminished lysis 
in the presence of each of the Bw4 + HLA-B alleles tested, 
and lysis was increased by the addition of the anti-NKB1 
monoclonal antibody. In contrast, while certain Bw6 reac- 
tive HLA-B alleles provided protection from lysis from some 
of the NKB1 + NK cell clones, none of these alleles inhibited 
all of the clones, and no clone was inhibited by all of the 
Bw6 + HLA-B alleles. Significantly, addition of the anti- 
NKB1 monoclonal antibody had no effect on lysis of these 
transfectants. Similarly, although HLA-A and HLA-C alleles 
inhibited some of the clones, this inhibition did not affect 
every done, and was not altered by the presence of the anti- 
body (Table 1). 
The observation that inhibition of NKB1 + clones requires 
an appropriate class I molecule and is prevented by the addi- 
tion of an antibody directed against he NKB1 molecule is 
suggestive of a receptor/ligand-like interaction between the 
NKB1 molecule and the class I molecule on the target cell 
Further evidence in support of this model is the demonstra- 
tion that addition of anti-class I monoclonal antibodies aug- 
ments lysis of transfectants to an extent identical to that ob- 
tained with the anti-NKB1 antibody (Fig. 2, a and b). One 
anti-class I monoclonal antibody to give this effect was DX15, 
which emerged from the same fusion and selection as the 
anti-NKB1 monoclonal antibody Dxg. The augmentation 
of NK cell mediated lysis seen in the presence of DX15 was 
not due to ADCC, since F(ab')2 fragments were used for all 
experiments. Several other well characterized anti-class I mono- 
clonal antibodies including MEI, MA2.1, and PA2.6 (34), 
also increase lysis of the HLA transfected target cells to which 
they bind (data not shown). 
The Effect of the Bw4 Epitope Is Modulated by Sequences El e- 
where in the Class I Molecule. If NKB1 is an HLA receptor, 
then the simplest interpretation of our finding that HLA- 
B'1513 inhibits lysis whereas B'1502 does not, is that the 
amino acid substitutions at positions 77-83 of the B'1502 
and B* 1513 heavy chains influence the aflhnity of the interac- 
tion with NKB1. This could be due to direct recognition 
of residues within this region, or to a conformational effect 
that substitutions within this region have on another site of 
the class I molecule. To investigate the influence of sequences 
outside the Bw4/Bw6 region on recognition by NKB1 + 
NK cell clones, we examined lysis of tranfectants expressing 
HLA-A*2403 and A'2501. These alleles are recognized by 
Bw4 alloantisera, nd analysis of their heavy chain sequences 
reveals that A'2403 is identical to B'1513 from positions 
75-83, while A'2501 is identical from residues 78-83 (Fig. 
3). However, both A'2403 and A'2501 differ substantially 
from HLA-B alleles in other parts of the heavy chain sequence 
(Fig. 3). 
Expression of A'2403 or A'2501 inhibited lysis by 9 of 
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Tab le  1. Comparison of HLA-A, -B, and-C Alleles Which 
React or Do Not React with NK Cells Bearing the NKBI 
Molecule 
Transfected Serological NKB1 § NK 
allele specificity cell reactivity 
B '5801 Bw4 + 
B* 5101 Bw4 + 
B '2705 Bw4 + 
B '1513 Bw4 + 
B* 1502 Bw6 - 
B '1501 Bw6 - 
B '3505 Bw6 - 
B '4801 Bw6 - 
B*0702 Bw6 - 
B '5401 Bw6 - 
B '5501 Bw6 - 
Cw*0102 Neither - 
Cw*0304 Neither - 
Cw*0801 Neither - 
Cw*0401 Neither - 
Cw'1503 Neither - 
A*0201 Neither - 
A '0211 Neither - 
A '3601 Neither - 
Alldes that react with NKB1 + NK cells (shown by + ) inhibit all NK 
cell dones that express NKB1, and addition of the anti-NKB1 monoclonal 
antibody augments lysis of these transfectants. Alleles that do not react 
with NKB1 + NK (shown by - ) cells do not inhibit all of the NKB1 + 
clones, and addition of the anti-NKB1 monoclonal antibody fails to in- 
crease killing. (Data indude transfectants ested in a previous study, 
reference 9). 
10 NKBI* clones from each donor (18 out of 20 clones 
total), but killing was not increased by addition of the anti- 
NKB1 antibody (Fig. 4, a-c). Thus two HLA-A alleles that 
possess the Bw4 epitope, interact differently with NKB1 + 
NK cells than do HLA-B alldes having this epitope. This 
could be due to qualitative differences inbinding or to quan- 
titative differences in affinity of these alleles for the NKB1 
molecule, such that the presence of the anti-NKB1 antibody 
does not prevent interaction with A'2403 and A*250L Al- 
ternatively, the NKB1 + NK cells which are inhibited by 
these alleles might possess another receptor which interacts 
with the two HLA-A alldes, but is not blocked by the anti- 
NKB1 monodonal antibody. 
The Presence of the Carbohydrate Moiety on the Class I Mole- 
cule Is Not Essential for Inhibition of NKBI + NK Cells. To 
investigate whether the absence of the carbohydrate moiety 
affects dass I mediated inhibition of NKB1 + NK calls, we 
performed site-directed mutagenesis on the glycosylation site 
of the B'5801 heavy chain (see Fig. 5). This class I molecule 
was chosen because NKB1 + NK cells were originally iso- 
lated from a B58 + donor, and dones bearing NKB1 were 
known to be specifically inhibited by B'5801 expression (9). 
Two mutants were made, one in which asparagine 86 was 
replaced by glutamine (B58.Q86) and one in which serine 
88 was replaced by alanine (B58.A88). The two mutants were 
transfected into 721.221 calls, and expression of the mutant 
molecules characterized. To assess the glycosylation state of 
the mutant heavy chains, immunoprecipitates were analyzed 
with and without neuraminidase and N-glycanase treatment. 
From the reduced molecular mass compared to the wild-type 
B'5801, and the lack of neuraminidase s nsitivity, it was ap- 
parent hat the B58.Q86 mutant was devoid of carbohydrate. 
A small proportion ('~10%) of the B58.A88 mutant heavy 
chains were glycosylated. 
Both mutants demonstrated aninhibitory effect on lysis 
by NKB1 + NK cells (Fig. 6, a and b). Addition of the anti- 
NKB1 monodonal ntibody reconstituted the level of killing 
to that of the untransfected 721.221 cells. Although both mu- 
tants clearly reduced lysis compared to the untransfected 
721.221, the inhibitory effect was not as strong as that ob- 
served with the wild-type B'5801 transfect. To investigate 
this difference further, the dass I cell surface xpression levels 
of the mutants were assessed by flow cytometric analysis using 
the monomorphic anti-class I antibody, W6/32. Both mu- 
tants had reduced call surface xpression compared with the 
a B'5801/721.221 
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Figure 2. Cell killing is aug- 
mented to the same deg,~e in the 
presence of anti-NKB1 antibodies 
and anti-dass I antibodies. Addition 
of both mAbs increases lysis of the 
transfectants to the level of killing 
of the untransfected 721.221 call 
line. Percent lysis of 721.221 trans- 
fectants by NKB1 + NK cell clones: 
without mAb (dark bars), with the 
addition of the anti-NKB1 mAb, 
DX9 (light grey bars), with the ad- 
dition of the anti-HLA m_Ab, DX15 (dar]e grey bars). (a) B'5801 trans- 
fectant; (b) B'1513 transfectant. All 
of the NK cell clones were estab- 
lished from a single blood donor. 
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Figure 3. Alignment of the 
amino acid sequences of the cx~ and 
ot2 domains of HLA-A, and B 
heavy chains. Dashes indicate ho- 
mology with the consensus se- 
quence. The boxed residues confer 
reactivity with Bw4 alloandsera. 
Polymorphic residues ofHLA-B al- 
leles which are thought to interact 
with bound peptides are indicated 
by V, those which are shared 
among the alleles which inhibit 
NKB1 + NK cells are marked by 
V. 
wild-type B* 5801 transfectant. The fluorescence intensity of 
the B58.A88 transfectant was ~5-fold lower than that of the 
wild type, whereas the B58.Q86 mutant was *10-fold lower 
(Fig. 7, a-c). From assessment of the results from multiple 
experiments, the degree of protection from lysis by an 
NKB1 + clone could be correlated with the level of class I 
expression at the target cell surface (R 2 = 0.88, n = 21), 
suggesting that the reduced inhibition by the mutant class 
I molecules was due to their decreased expression. 
To rule out the possibility of a protective ffect mediated 
by elevated expression of class I molecules lacking 32- 
microglobulin, the amount of free class I heavy chain on the 
cell surface of the B58 mutant ransfectants was assessed by 
indirect flow cytometry using Q1/28. This monoclonal an- 
tibody binds predominantly to class I heavy chains that are 
not associated with 132-microglobulin (35). The intensity of 
staining with the Q1/28 antibody was proportional to the 
total amount of class I on the cell surface as measured by 
W6/32 staining, and neither mutant appeared to have elevated 
levels of flee heavy chain compared to the wild-type B'5801 
transfectant (data not shown). 
These experiments demonstrate hat the inhibitory effect 
of B'5801 on NKB1 § NK cells does not require the pres- 
ence of the carbohydrate moiety. The inhibitory effect of the 
B58.A88 mutant could be due to recognition of the subpopu- 
lation of glycosylated forms of this molecule, however inhi- 
bition was also observed with the B58.Q86 mutant which 
completely lacks glycosylated forms, indicating that the car- 
bohydrate moiety is not essential for recognition. Moreover, 
it is striking that the mutant B58 molecules provided protec- 
tion from lysis by NKB1 + NK clones, despite being present 
at significantly reduced cell surface expression levels. 
Discussion 
The data presented here demonstrate hat the Bw4 epi- 
tope is critical for recognition by NK cells which express the 
NKB1 antigen. All of the HLA-B alleles tested which bear 
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the Bw4 epitope inhibit NKB1 + NK cells, while HLA-A 
and -C alleles and HLA-B alleles with the Bw6 epitope do 
not. Furthermore, inhibition can be prevented by the binding 
of an antibody either to the NKB1 molecule, or to the class 
I molecule. These observations suggest NKB1 is an inhibi- 
tory receptor with specificity for the Bw4 epitope of HLA-B 
alleles, however proof of this thesis awaits direct demonstra- 
tion of NKB1 binding to the class I molecule. 
If the NKB1 molecule is a class I receptor, the residues 
at positions 77-83 of the class I heavy chain must influence 
recognition, since HLA-B*1502 and B*15D differ only in 
this region. Recognition of inhibitory HLA-C alleles by NK 
cells which express the p58 molecules also appears to be based 
on differences at positions 77 and 80 of the class I molecule 
(8). Therefore, NKB1 and the p58 molecules may recognize 
a similar region of the class I molecule. Moreover, Storkus 
et al. found that the presence of His at position 74 of the 
class I heavy chain affected recognition of HLA-A*0201 by 
NK cells (5). Thus the carboxy-terminal half of the o~1 helix 
is consistently implicated in NK cell recognition of class I 
molecules. 
Residues 77-83 comprising the Bw4 epitope may repre- 
sent the NKBl-binding site, or substitutions in this region 
may affect the conformation of an NKBl-binding site else- 
where on the class I molecule. Residues within the 77-83 
segment can contribute to interactions with the bound pep- 
tide, and it is also possible that differences in the peptides 
bound by HLA-B*1502 and B* 1513 contribute ither directly 
or indirectly to the conformation of the NKBl-binding site. 
Viral infection of HLA transfectants renders them suscep- 
tible to lysis by NK cells (36), and hence the ability to detect 
differences inbound peptides might be a mechanism by which 
NK cells recognize viraUy infected cells. 
Class I molecules bind peptides in an allele-specific manner, 
with polymorphic residues within the peptide-binding groove 
conferring selectivity. Residues 77, 80, and 81 within the 
Bw4/Bw6 region are predicted to interact with bound pep- 
tides. The COOH-terminal amino acid of the peptide binds 
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Figure 4. The inhibitory effect of HLA-A alleles which possess the Bw4 
epitope isnot affected by the addition of the anti-NKB1 monodonal nti- 
body. Percent lysis of class I HLA transfected 721.221 target cells by 
NKB1 + NK cell clones: (a) untransfected 721.221; (b) A'2403 transfec- 
rant; and (c) A'2501 transfectant. Dark bars show killing in the absence 
of the anti-NKB1 mAb, DX9. Light bars show killing in the presence 
of Dxg. All of the NK cell clones were stablished from a single blood onor. 
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near these positions, so the substitutions which define the 
Bw4 and Bw6 epitopes may affect the identity of the last 
residue of the peptide. Peptide binding motifs have been ana- 
lyzed for HLA-B*3501 and B'5301 which differ, like B'1502 
and B'1513, only in the 77-83 region. B'5301 possesses the 
Bw4 epitope; B'3501 has the Bw6 epitope. Hill et al. found 
by sequence analysis of the pool ofpeptides eluted from B'3501 
that tyrosine was the only amino acid selected at the COOH 
terminus, whereas 8"5301 had no amino acid preferences at
this position (37). However, a subsequent analysis by Falk 
et al. identified hydrophobic residues as well as tyrosine at 
the COOH-terminal residue ofB*3501-binding peptides (38). 
Thus the influence of polymorphism within the Bw4/Bw6 
region of the class I heavy chain on the bound peptide reper- 
toire is not yet understood. 
Apart from the shared Bw4 epitope there is little overall 
similarity in the peptide-binding site of the HLA-B mole- 
cules recognized by NKB1 + NK cells. B'5801, B'5101, 
B'2705, and B'1513 have the same residue at only 6 of the 
25 polymorphic peptide binding positions of the oq and c~2 
domains of HLA-B molecules (Fig. 3). In pairwise compar- 
isons B'5801 and B'5101 each differ from B'1513 at several 
peptide binding positions, and differ from each other at 11. 
Furthermore analysis of peptides bound to B'2705 showed 
that this allele has a preference for peptides with arginine 
at the second position, while B'5101 binds peptides with 
proline at this position (37, 39, 40). Therefore it seems un- 
likely that these alleles bind a common set of peptides. Chad- 
wick and Miller (41) and Storkus et al. (42) have suggested 
that self peptides complexed with class I molecules are re- 
quired for inhibition of NK cell-mediated lysis. The diverse 
peptide binding characteristics of the four alleles recognized 
by NKB1 + NK cells suggest hat class I binding of partic- 
ular peptides derived from endogenous proteins is probably 
not necessary for recognition by this receptor. Likewise, rec- 
ognition of HLA-C may not depend on the presence of specific 
bound peptides, since the sequences of the peptide pool eluted 
from HLA-C molecules reveal no correlation with NK cell 
reactivity (43). However, changes to the overall repertoire 
of bound peptides, such as could occur upon viral infection, 
might affect NKB1 recognition of class I molecules. 
It is also possible instead that bound peptides do not 
influence HLA recognition by NK cells, and that the receptors 
recognize the class I molecule directly. Five related sequence 
motifs are found at positions 77-83 among HLA alleles with 
the Bw4 epitope, while alleles possessing the Bw6 epitope 
are invariant in this region, with the exception of B'7301 
(Table 2). Two of the more divergent motifs are included 
among the alleles which inhibit NKB1 § NK cells (Table 2 
and Fig. 3), suggesting that conserved features of the Bw4 
epitope may account for the observed NK cell reactivity. Class 
I alleles with the Bw4 epitope all possess leucine and argi- 
nine at positions 82 and 83, respectively, while those alleles 
which do not possess the Bw4 epitope xpress arginine and 
glycine respectively at these positions. Positions 82 and 83 
are located on the "outer" face of the or1 helix, and are 
postulated to be solvent accessible (44). Therefore these po- 
sitions are candidates for direct recognition, and the presence 
,./y---~'ye 
39 
2O 90 
O9 
54 
177! 
f7 
S5 
179 
hTz 
31 
301 
119 
20 
121 
22 
138 
85 
N 
106 
104 
)5 109 
110 
I l l  
f3f 
130 
f33 
132 
i1~137 
Figure 5. Ribbon diagram showing the cq and c~2 domains of the class I molecule. Numbers correspond to amino acid positions of the mature 
heavy chain. The polymorphic residues which determine the Bw4 serological epitope are darkened. The single site of N-linked glycosylation atposition 
86 is indicated by "CHO". 
of leucine and/or arginine at positions 82 and 83 of the class 
I heavy chain may be key in determining NKB1 reactivity 
Employing a genetic approach to study a recombinant 
family, Celia et al. (45) have also observed a pattern of HLA 
recognition by NK cell clones which appears to focus on the 
Bw4 epitope. Using mitogen stimulated lymphocytes from 
a pand of HLA-typed donors as target cells, resistance to lysis 
was correlated with the presence of the Bw4 epitope on ei- 
ther HLA-A or -B molecules. The authors concluded that 
Bw4 motifs which have an isoteucine at position 80 are 
strongly inhibitory, whereas those that have threonine at this 
position provide only moderate inhibition. Our results how 
that although Bw4 + HLA-A molecules are inhibitory, this 
inhibition is not prevented by addition of the anti-NKB1 
monodonal antibody Therefore the inhibitory effect of 
Bw4 + HLA-A alleles could well be due to the presence of 
another HLA receptor on the NK cell clones, in addition 
to NKB1. In the analysis by Celia et al. this second receptor 
might show specificity for the Bw4 motif of HLA-A mole- 
cules. Most of the target cells tested by Cella et al. which 
are strongly refractory to lysis express a Bw4 + HLA-A al- 
lele. If these samples were to be excluded from the analysis 
in order to assess just HLA-B alleles, then there is no longer 
a strong correlation of resistance to lysis with the presence 
of isoleucine at position 80, since HLA-B alleles having ei- 
ther isoleucine or threonine gave strong inhibition in their 
investigation. Similarly, we find moderate inhibition by an 
allele which has isoleucine at position 80 (B*1513) as well 
as by B'2705 which has threonine at this position (Table 2). 
On the other hand, HLA-B*5101 and B'5801 both of which 
have isoleucine at position 80 usually mediate strong inhibi- 
tion in our experiments. Thus, the degree of inhibition medi- 
ated by the Bw4 epitope of HLA-B molecules may be 
influenced by additional features of the class I molecule out- 
side of the Bw4/Bw6 epitope. It is clear that there a number 
of different NK cell receptors for class I molecules and that 
individual NK cell clones can express more than one receptor. 
Given this potential complexity at the level of the NK cell, 
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Figure 6. Lysis by an NKB1 § NK cell clone is inhibited by expres- 
sion of mutant HLA-B58 molecules which are not glycosylated. Effector 
to target itration curves of cell killing assays performed with an NKB1 + 
NK cell clone, in the presence and absence of the anti-NKB1 monoclonal 
antibody Dxg. (a) Percent lysis of the B*58.A88 mutant. (b) Percent lysis 
of the B*58.Q86 mutant. The level of killing of the untransfected 721.221 
cell line is shown for comparison. 
there are additional difficulties in analyzing the class I 
specificities of any one receptor using target cells expressing 
up to six potential class I HLA ligands, as is the case for 
mitogen-stimulated lymphocytes. For this reason we elected 
to analyze the specificity of the NKB1 receptor for class I 
molecules using transfectants each expressing a single class 
I allele. 
We find that the presence of the carbohydrate moiety is 
not essential for class I recognition by NK cells expressing 
the NKB1 molecule. This result is in agreement with the 
finding by Storkus et al. that polyclonal NK cells were in- 
hibited by the expression of a mutant HLA-B*0702 mole- 
cule lacking the glycosylation site at position 86 of the heavy 
chain (46). Previous tudies have also observed reduced cell 
surface xpression of class I molecules lacking glycosylation 
(21, 22). The observation that class I glycosylation is not 
needed for NKB1 § NK cell recognition suggests that the 
carbohydrate moiety is not bound by the receptor. Since the 
gene for NKB1 has yet to be cloned, it is not known whether 
NKB1 is homologous to the murine NK cell receptor for 
H-2D Ly-49, which encodes a lectin-like domain. However, 
structural distinctions between Ly-49 and NKB1 are already 
apparent; Ly-49 is a disulfide-linked homodimer with subunits 
of 44 kD, whereas NKB1 is a single chain of 70 kD (9, 47). 
It will also be of interest o determine whether the lectin- 
like domain of Ly-49 binds a carbohydrate moiety of the class 
I molecule. 
Recognition of class I HLA by NK cells which bear the 
NKB1 antigen appears to be fundamentally different from 
class I recognition by T cells. Antigen-specific T cells recog- 
nize individual peptide + MHC complexes, whereas 
NKB1 + NK cells appear to recognize apublic determinant 
on class I molecules. K~rre et al. (2) have proposed that the 
function of NK cell recognition of MHC antigens i to elim- 
inate cells which lack a "self" marker. However, this hypoth- 
esis does not account for the observation that NK cells dis- 
criminate class I alleles, since elimination of pathogens or cells 
lacking normal class I expression could be accomplished by 
monomorphic recognition of HLA molecules. One function 
for NK cell recognition of polymorphic class I epitopes could 
be to facilitate detection of differences in peptide presenta- 
tion that result from infection by intraceUular parasites. How- 
ever, the ability to discriminate polymorphic self antigens could 
also be beneficial without involving peptide presentation. NK 
cells are part of the early immune response to an invading 
pathogen. If NK cells kill target cells because they lack self 
HLA antigens, pathogenic microorganisms could evade de- 
tection by mimicking conserved HLA epitopes. However, if 
subsets of NK cells recognize polymorphic epitopes of different 
HLA molecules effective molecular mimicry would be more 
difficult, because a pathogen would need to mimic epitopes 
of 3-6 HLA-A, -B, and -C molecules to escape detection by 
all NK cells. Additionally, recognition of polymorphic de- 
terminants allows detection of autologous cells which have 
lost expression of only one or two class I alleles, as occurs 
in certain tumors and virus infections. 
During the evolution of HLA-B polymorphism, gene con- 
version events appear to have focused on the region of class 
I genes which encodes the Bw4 and Bw6 epitopes, resulting 
in the formation of at least 10 pairs of recombinant HLA-B 
alleles differing only in this region. The ability to interact 
with a certain subpopulation ofNK cells may contribute to 
the selection pressures which have driven these gene conver- 
sion events. The Bw4 epitope i s present on ,v35% of the 
HLA-B antigens identified thus far, and HLA-B molecules 
that possess the Bw4 epitope are present at a gene frequency 
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Figure 7. Two HLA-B58 glyco- 
syhtion site mutants transfected into 
the 721.221 cell line have reduced 
cell surface xpression, compared to 
the wild-type B'5801 transfectant. 
FACS histograms of721.221 trans- 
fectant staining with the anti-class 
I antibody W6/32. The light histo- 
gram trace on the left indicates back- 
ground staining of the untransfected 
721.221 cell line. Transfectant 
staining is shown by the dark histo- 
gram trace. Fluorescence and cell 
number are presented in arbitrary 
units. The median fluorescence in- 
tensifies were as follows: 721.221 = 
5.6; B'5801 transfectant = 299.6; 
10 + B58.A88 transfectant = 75.0; 
B58.Q86 transfectant = 30.8. 
of "~40% in many populations, including North American 
whites and blacks, and non-Chinese Thais (48). It is possible 
that selection by NKB1 § NK cells has contributed to main- 
tenance of these gene frequencies. 
Understanding features of class I molecules that are im- 
portant in NK cell recognition, and the distinctions between 
class I recognition by NK cells and T cells may be helpful 
in medical practice. Both NK cells and T cells are cytotoxic 
for hematopoietic cells in vivo, and are potential mediators 
of bone marrow graft rejection. In rodent models the study 
of bone marrow rejection suggests that interaction between 
NK cells and class I molecules of the target cell may be im- 
portant in determining the success of the transplant (49, 50). 
In these models, grafts lacking certain self alleles may be re- 
jected by the recipient, although no foreign alleles are present 
on the donated marrow cells (51). The rejection is mediated 
by host NK cells, that are more resistant to radiation than 
T cells or B cells, and is thought o result from a lack of 
inhibition provided by the "missing" self determinants (51). 
Further investigation is necessary to determine the role of 
NK cells in human bone marrow graft rejection, GVHD, 
and in eliminating leukemic ells. HLA-matching procedures 
and immunosuppressive drugs have made rejection un- 
common, however GVHD and recurrence of leukemia re- 
main a problem. T cell depletion reduces the likelihood of 
GVHD, but increases the incidence of graft rejection and leu- 
kemic relapse (52). If NK ceils prove to be involved in these 
processes, clarification of the class I epitopes recognized by 
NK cells may facilitate assessment of the extent of matching 
required for successful bone marrow transplantation between 
unrelated onors and recipients. 
Table 2. Class I HLA Sequence Motifs Determining the Bw4 and Bw6 Serological Epitopes 
Class I position 
Serological 
epitope Class I locus 77 80 81 82 83 Tested HLA allele 
Bw4 HLA-A,B N I A L R 
HLA-B N T A L R 
HLA-A S I A L R 
HLA-B S T L L R 
HLA-B D T L L R 
Bw6 HLA-B S N L R G 
HLA-B G N L R G 
B'5801, B'5101, B'1513, A'2403 
A'2501 
B'2705 
B'1502 
Only polymorphic positions within these epitopes are shown. 
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